Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus between Hospital Dermatologists and Pharmacists
Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v2i1.1812
Abstract
Atopic dermatitis is one of the most common dermatologic conditions and its treatment is often challenging. To establish consensus on recommendations for responding to various situations that arise when treating atopic dermatitis, a group of hospital pharmacists and dermatologists used the Delphi process. A scientific committee developed a Delphi survey with two blocks of questions to explore the group's views on (1) evaluating response to treatment in the patient with atopic dermatitis and (2) cooperation between the dermatology department and the hospital pharmacy service. The experts achieved an overall rate of consensus of 86% during the process. Conclusions were that dermatologists and hospital pharmacists need to maintain good communication and coordinate their interventions to optimize the management of atopic dermatitis and patients' responses to treatment.
Keywords
atopic dermatitis; dermatology; pharmacy service hospital; patient care management; treatment; clinical practice guidelines; quality of health care
Funding
This research project was financed by Lilly S.A.
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Cabanillas B, Brehler AC, Novak N. 2017. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Clin Allergy Immunol, 17: 309-315.
[2] Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. 2017. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol, 27: 78-88. http://dx.doi.org/10.18176/jiaci.0138.
[3] Severity scoring of atopic dermatitis: the SCORAD index. 1993. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 186: 23-31. http://dx.doi.org/10.1159/000247298.
[4] European Federation of Allergy and Airways Diseases Patients' Associations (EFA). Itching for quality of life and costs for people with severe atopic eczema in Europe. 2018. https://www.efanet.org/news/3373-european-report-itching-for-life-quality-of-life-and-costs-for-people-with-severe-atopic-eczema-in-europe
[5] Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. 2020. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol, 100: 320-329.
[6] Sicras-Mainar A, Navarro-Artieda R, Sánchez L, Sastre J. 2018. Prevalence of severe atopic dermatitis in adults in 3 areas of Spain. J Invest Allergol Clin Immunol, 28: 195-197. http://dx.doi.org/10.18176/jiaci.0234.
[7] Silverberg JI, Hanifin JM. 2013. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol, 132: 1132-1138. http://dx.doi.org/10.1016/j.jaci.2013.08.031.
[8] Carrascosa JM, Morillas-Lahuerta V. 2020. Comorbilidades en dermati-tis atópica: actualización y controversias. Actas Dermosifiliogr, 111: 481-486. http://dx.doi.org/10.1016/j.ad.2020.04.009.
[9] Informe técnico: situación actual de la dermatitis atópica grave. Fundamed y Alianza General de Pacientes. 2018. https://alianzadepacientes.org/wp-content/uploads/2020/03/Informe-Dermatitis-atopica-grave.pdf
[10] Hasson F, Keeney S, McKenna H. 2000. Research guidelines for the Delphi survey technique. J Adv Nurs, 32: 1008-1015.
[11] Morisky DE, Green LW, Levine DM. 1986. Concurrent and predictive validity of a self-reported measure of T716 medication adherence. Med Care, 24: 67-74. http://dx.doi.org/10.1097/00005650-198601000-00007.
[12] Mocanu M, Vât˘a D, Alexa AI, Trandafir L, Patrascu AI, Hâncu MF, et al. 2021. Atopic dermatitis - beyond the skin. Diagnostics (Basel), 11: 1553. http://dx.doi.org/10.3390/diagnostics11091553.
[13] Martín Mateos MA. 2012. Guía de tratamiento de la dermatitis atópicaen el nino. In: Documento de Consenso. Grupo de expertos. 2.aed. Ergon.
[14] Senán Sanz MR, Pelegrín López B. 2022. Guía de consulta rápida endermatitis atópica. 2.aed. Madrid: IMC&A.
[15] Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, DeleuranM, Fink-Wagner A, et al. 2018. Consensus-based European guide-lines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J Eur Acad Dermatol Venereol, 32: 850-878. http://dx.doi.org/10.1111/jdv.14888.
[16] Bieber T. 2022. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov, 21: 21-40. http://dx.doi.org/10.1038/s41573-021-00266-6
[17] Otero Torres S, Serra Baldrich E, Padullés Zamora N, Suárez-Lledó Grande A, San-tacana Juncosa E, ComasSugranes D. 2020. Agentes biológicos aprobados y en desarrolloclínico para el tratamiento de la dermatitis atópica. El Farmacéutico Hospitales, 217: 10-20. https://www.elfarmaceuticohospitales.es/actualidad/en-profundidad/item/6724-agentes-biologicos-aprobados-y-en-desarrollo-clinico-para-el-tratamiento-de-la-dermatitis-atopica#.YtZnXZBw2w
[18] Cohen J, Rivera J, de Paz H, Aceituno S. 2021. Iniciativa estratégica desalud ViDA: Vivir con Dermatitis Atópica. https://media.iese.edu/research/pdfs/ST-0619
[19] Armario-Hita JC, Artime E, Vidal-Vilar N, Huete T, Díaz-Cerezo S, Moro RM, et al. 2022. Medidas del resultadoreportadas por el paciente en estudios sobre dermati-tis atópica en Espa˜a, en condiciones del mundo real: revisión sistemática. Actas Dermo-Sifiliogr, 113: 685-704. http://dx.doi.org/10.1016/j.ad.2022.01.025.
[20] Conde-Taboada A, Aranegui Arteaga B, Sam Cernac AC. 2020. Asthma and $$: is a multidisciplinary approach possible? Open Respir Archiv, 2: 100-101. http://dx.doi.org/10.1016/j.opresp.2020.05.010.
[21] Morillo-Verdugo R, Margusino-Frami˜án L, Monte-Boquet E, Morell-Baladrón A, Barreda-Hernández D, Rey-Pineiro XM, et al. 2020. Spanish society of hospital pharmacy position statement on telepharmacy: recommendations for its implementation and development. Farm Hosp, 44: 174-181. http://dx.doi.org/10.7399/fh.11515.
[22] Koster ES, Philbert D, Wagelaar KR, Galle S, BouvyML. 2019. Optimizing pharmaceutical care for pediatric patients with dermatitis: perspectives of parents and pharmacy staff. Int J Clin Pharm, 41: 711-718. http://dx.doi.org/10.1007/s11096-019-00827-1.
[23] Mesa-Álvarez L, Batalla A, Fernández-Torres R. 2019. Atopic dermatitis school: the importance of training for caregivers. Piel, 34: 390-395.
[24] Nankervis H, Thomas KS, Delamere FM, Barbarot S, RogersNK, Williams HC. 2016. Scoping systematic review of treatments for eczema. Southampton (UK): NIHR Journals Library.
[25] Silvestre JF. 2018. Sobre la necesidad y el futuro de las Unidades de Eczema. Actas Dermosifiliogr. 109: 465-467. https://www.actasdermo.org/es-sobrenecesidad-el-futuro-unidades-articulo-S000173101830293XT717
[2] Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. 2017. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol, 27: 78-88. http://dx.doi.org/10.18176/jiaci.0138.
[3] Severity scoring of atopic dermatitis: the SCORAD index. 1993. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 186: 23-31. http://dx.doi.org/10.1159/000247298.
[4] European Federation of Allergy and Airways Diseases Patients' Associations (EFA). Itching for quality of life and costs for people with severe atopic eczema in Europe. 2018. https://www.efanet.org/news/3373-european-report-itching-for-life-quality-of-life-and-costs-for-people-with-severe-atopic-eczema-in-europe
[5] Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. 2020. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol, 100: 320-329.
[6] Sicras-Mainar A, Navarro-Artieda R, Sánchez L, Sastre J. 2018. Prevalence of severe atopic dermatitis in adults in 3 areas of Spain. J Invest Allergol Clin Immunol, 28: 195-197. http://dx.doi.org/10.18176/jiaci.0234.
[7] Silverberg JI, Hanifin JM. 2013. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol, 132: 1132-1138. http://dx.doi.org/10.1016/j.jaci.2013.08.031.
[8] Carrascosa JM, Morillas-Lahuerta V. 2020. Comorbilidades en dermati-tis atópica: actualización y controversias. Actas Dermosifiliogr, 111: 481-486. http://dx.doi.org/10.1016/j.ad.2020.04.009.
[9] Informe técnico: situación actual de la dermatitis atópica grave. Fundamed y Alianza General de Pacientes. 2018. https://alianzadepacientes.org/wp-content/uploads/2020/03/Informe-Dermatitis-atopica-grave.pdf
[10] Hasson F, Keeney S, McKenna H. 2000. Research guidelines for the Delphi survey technique. J Adv Nurs, 32: 1008-1015.
[11] Morisky DE, Green LW, Levine DM. 1986. Concurrent and predictive validity of a self-reported measure of T716 medication adherence. Med Care, 24: 67-74. http://dx.doi.org/10.1097/00005650-198601000-00007.
[12] Mocanu M, Vât˘a D, Alexa AI, Trandafir L, Patrascu AI, Hâncu MF, et al. 2021. Atopic dermatitis - beyond the skin. Diagnostics (Basel), 11: 1553. http://dx.doi.org/10.3390/diagnostics11091553.
[13] Martín Mateos MA. 2012. Guía de tratamiento de la dermatitis atópicaen el nino. In: Documento de Consenso. Grupo de expertos. 2.aed. Ergon.
[14] Senán Sanz MR, Pelegrín López B. 2022. Guía de consulta rápida endermatitis atópica. 2.aed. Madrid: IMC&A.
[15] Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, DeleuranM, Fink-Wagner A, et al. 2018. Consensus-based European guide-lines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J Eur Acad Dermatol Venereol, 32: 850-878. http://dx.doi.org/10.1111/jdv.14888.
[16] Bieber T. 2022. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov, 21: 21-40. http://dx.doi.org/10.1038/s41573-021-00266-6
[17] Otero Torres S, Serra Baldrich E, Padullés Zamora N, Suárez-Lledó Grande A, San-tacana Juncosa E, ComasSugranes D. 2020. Agentes biológicos aprobados y en desarrolloclínico para el tratamiento de la dermatitis atópica. El Farmacéutico Hospitales, 217: 10-20. https://www.elfarmaceuticohospitales.es/actualidad/en-profundidad/item/6724-agentes-biologicos-aprobados-y-en-desarrollo-clinico-para-el-tratamiento-de-la-dermatitis-atopica#.YtZnXZBw2w
[18] Cohen J, Rivera J, de Paz H, Aceituno S. 2021. Iniciativa estratégica desalud ViDA: Vivir con Dermatitis Atópica. https://media.iese.edu/research/pdfs/ST-0619
[19] Armario-Hita JC, Artime E, Vidal-Vilar N, Huete T, Díaz-Cerezo S, Moro RM, et al. 2022. Medidas del resultadoreportadas por el paciente en estudios sobre dermati-tis atópica en Espa˜a, en condiciones del mundo real: revisión sistemática. Actas Dermo-Sifiliogr, 113: 685-704. http://dx.doi.org/10.1016/j.ad.2022.01.025.
[20] Conde-Taboada A, Aranegui Arteaga B, Sam Cernac AC. 2020. Asthma and $$: is a multidisciplinary approach possible? Open Respir Archiv, 2: 100-101. http://dx.doi.org/10.1016/j.opresp.2020.05.010.
[21] Morillo-Verdugo R, Margusino-Frami˜án L, Monte-Boquet E, Morell-Baladrón A, Barreda-Hernández D, Rey-Pineiro XM, et al. 2020. Spanish society of hospital pharmacy position statement on telepharmacy: recommendations for its implementation and development. Farm Hosp, 44: 174-181. http://dx.doi.org/10.7399/fh.11515.
[22] Koster ES, Philbert D, Wagelaar KR, Galle S, BouvyML. 2019. Optimizing pharmaceutical care for pediatric patients with dermatitis: perspectives of parents and pharmacy staff. Int J Clin Pharm, 41: 711-718. http://dx.doi.org/10.1007/s11096-019-00827-1.
[23] Mesa-Álvarez L, Batalla A, Fernández-Torres R. 2019. Atopic dermatitis school: the importance of training for caregivers. Piel, 34: 390-395.
[24] Nankervis H, Thomas KS, Delamere FM, Barbarot S, RogersNK, Williams HC. 2016. Scoping systematic review of treatments for eczema. Southampton (UK): NIHR Journals Library.
[25] Silvestre JF. 2018. Sobre la necesidad y el futuro de las Unidades de Eczema. Actas Dermosifiliogr. 109: 465-467. https://www.actasdermo.org/es-sobrenecesidad-el-futuro-unidades-articulo-S000173101830293XT717
Copyright © 2024 P. Herranz-Pinto, I. Figueras Nart, E. Monte-Boquet, B. Tortajada Goitia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License